Gulseren Guzel
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
Journal: ESMO open
Published: December 21, 2023
Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 15, 2023
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
Journal: JTO clinical and research reports
Published: October 26, 2022
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
Journal: ESMO open
Published: June 09, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
Journal: Journal for immunotherapy of cancer
Published: May 02, 2021
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Journal: Future oncology (London, England)
Published: September 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
Journal: Journal for immunotherapy of cancer
Published: April 07, 2020
Evaluation of the potential for QTc prolongation with avelumab.
Journal: Cancer chemotherapy and pharmacology
Published: July 23, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026